Analyzing...
Loading company...
Sai Life Sciences Ltd offers contract research and manufacturing services for the pharmaceutical industry. The company provides end-to-end solutions in drug development, analytical services, and production support for global clients.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,192 Cr revenue.
COGS 26.0%, employees 31.2%.
“revenues stood at $5.”
“Y o Y increase of 27% compared to $4.”
“Profit after tax for the quarter was INR100 crores, up 86% year on year.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 14.1%▲ | 10.3% |
| ROCE | 18.1%▲ | 13.7% |
| Net Margin | 15.6%▲ | 7.6% |
| EBITDA Margin | 30.0%▲ | 15.4% |
| Debt To Equity | 0.04x▼ | 0.15x |
| (₹ Cr) | TTM | FY2025 |
|---|---|---|
| Revenue | ₹2,192 Cr +29.4% | ₹1,695 Cr |
| Other Income | ₹49 Cr +33.6% | ₹37 Cr |
| Total Income | ₹2,242 Cr +29.5% | ₹1,731 Cr |
| COGS | ₹571 Cr +22.6% | ₹466 Cr |
| ₹1,767 Cr +17.5% | ₹1,504 Cr | |
| Profit Before Tax | ₹466 Cr +104.7% | ₹228 Cr |
| Exceptional Items | (₹8 Cr) | ₹0.00 Cr |
| ₹117 Cr +103.7% | ₹58 Cr | |
| Net Profit | ₹349 Cr +105.1% | ₹170 Cr |
| Profit (Owners) | ₹349 Cr +105.1% | ₹170 Cr |
| Other Comprehensive Income | (₹21 Cr) ↓ Decline | ₹1 Cr |
| EPS | ₹16.57 | ₹8.16 |
| Diluted Shares | ₹21 Cr | ₹21 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Sai Life Sciences Limited has informed the Exchange about Schedule of meet
Sai Life Sciences Limited has informed the Exchange regarding Allotment of 8900 Shares.
SAILIFE: Sai Life Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.
Sai Life Sciences Limited has informed the Exchange about Schedule of meeting with analyst / Investor on 3rd and 4th June 2026 at Mumbai
Sai Life Sciences Limited has informed the Exchange about Transcript of Earnings Call for the Audited Financial Results of the Company for the quarter and year ended 31 March 2026.
Sai Life Sciences Limited has informed the Exchange regarding Allotment of 92000 Shares under ESOP Schemes of the Company.
Monitoring Agency Report for the quarter and year ended 31 March 2026
Sai Life Sciences Limited has informed the Exchange about Investor Presentation
Sai Life Sciences Limited has informed the Exchange regarding a press release dated May 11, 2026, titled "Achievement of 100% Renewable Power at Bidar Campus of theCompany".
Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026
Intimation of an Order dated 29th April 2026 issued by the Joint Commissioner of Commercial Taxes (Appeals), Kalaburagi u/s 107 (11) of the Central Goods and Services Tax Act, 2017 and the Karnataka G...
Sai Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Sai Life Sciences Limited has informed the Exchange regarding Allotment of 11,100 Equity Shares under ESOP 2008 Scheme of the Company.
Sai Life Sciences Limited has informed the Exchange about an order dated 18th March 2026 passed by the Deputy Commissioner of Income Tax (International Taxation) Hyderabad u/s 201 (1) of the Income Ta...
Sai Life Sciences Limited has informed the Exchange about Schedule of meet
No dividend history available for this company.